MedTrace Logo

A Pilot Study of Terazosin for Parkinson's Disease

NCT03905811 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2022-05-16

Study results available
· View outcomes & findings →

Summary

The TZ-PD trial will be a 1:1 (active:placebo) randomized, double-blind, placebo-controlled Phase II trial to evaluate the safety and tolerability of terazosin for the treatment of PD.

Conditions

  • Parkinson Disease

Interventions

DRUG

Terazosin 5 MG

5 milligrams by mouth daily at bedtime

DRUG

Placebo oral capsule

1 capsule by mouth daily at bedtime

Sponsors & Collaborators

  • University of Iowa

    collaborator OTHER

  • Jordan Schultz

    lead OTHER

Principal Investigators

  • Jordan Schultz, PharmD · University of Iowa

  • Nandakumar Narayanan, MD, PhD · University of Iowa

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-24
Primary Completion
2020-06-05
Completion
2020-11-18
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03905811 on ClinicalTrials.gov